Press Room

News / Jun 22, 2017

Hovione receives B Corp Certification

Hovione became a Certified B Corp at the B Corp Summer Summit 2017, in Cascais, Portugal

B Corporation Certification logo | Hovione

Hovione is the first Chemical/Pharmaceutical Company integrating this innovative community of companies that use the power of business to solve social and environmental problems.

As a Certified B Corporation Hovione wants to contribute to redefine success in business, meeting the highest standards of social and environmental performance, setting its team members for success and personal satisfaction and aspiring to use the power of markets to solve social and environmental problems. Hovione believe that B Corps, and especially those that are family businesses, through the power of their collective voice, are competing to be Best for the World® and through them society will enjoy a more shared and durable prosperity.

To certify as a B Corp, a set of rigorous social and environmental standards must be met. This is achieved through the B Impact Assessment process that requires four principle areas to be assessed: governance model, workers, environment protection and community involvement, including the impact on its suppliers. Hovione's certification process began almost a year ago. During this period B Lab assessed Hovione's policies and procedures in all locations with its operations around the world (Portugal, Ireland, United States and Asia). They concluded that Hovione follows all the appropriate models and can thus be part of this movement.

This is a global movement of people using business as a force for goodTM with a vision that one day all companies compete not only to be the best in the world, but the Best for the World®.

 

Hovione receives B Corp Certification | Hovione
Sofia Burnay, Carolina Serras Pereira, Marcello Palazzi and Diane Villax

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024